2015, Number 4
<< Back Next >>
Rev Odont Mex 2015; 19 (4)
Cyclic neutropenia. Clinical case report
Oliva OKI, Magaña BV, Fragoso RR, Cuairán RV
Language: Spanish
References: 20
Page: 246-252
PDF size: 356.97 Kb.
ABSTRACT
Cyclic neutropenia occurs due to the fluctuation of cellular production levels of bone marrow stem cells. This is to say, they change during the cycle, and although numbers are recurrently low, function is normal. Cyclic neutropenia was first described by Leale in 1910 with dominant autosomal character. It manifests approximately every 21 days, with range of 14 to 36 days, lasting 3-6 days per episode. During the time when there are few circulating neutrophils, the patient is susceptible to infections. The clinical picture of this process includes: susceptibility to infection, feverish conditions, oral ulcers, impetigo, increased lymph nodes, periodontitis and stomatitis. It is important to stomatologically handle these patients; after inter-consultation with treating physician, prevent infection in a prophylactic scheme based on amoxicillin 50 mg/per kg weight or clindamycin 20 mg/per kg weight, review recent blood count results (maximum ten days before treatment). In emergency treatments pain and infection will be handled conservatively, with use of 0.12% chlorhexidine mouthwashes and Philadelphia solution when necessary.
REFERENCES
Bello A. Hematología básica. 3ra edición. México: Prado; 2004. pp. 201-204.
Quie M, Roberts R. Disorders of the polymorphonuclear phagocytic system. In: Stiehm ER, eds. Immunologic disorders in infants and children. 4th edition. Philadelphia: B. Saunders Company; 1996. pp. 443-468.
Inventario de archivos por serie documental, incidencias médicas del Hospital Infantil de México “Federico Gómez” 2004-2009, Departamento de Hematología, libro 3S.3.8.
Padron Y, Marsan V. Defectos en la fagocitosis: aspectos clínicos, moleculares y terapéuticos. Rev Cubana Hematol e Inmunol Hemoter. 2004; 20 (1).
Little JW, Falace DA. Tratamiento odontológico del paciente bajo tratamiento médico. 5ta edición. España: Ed. Harcourt; 2001. pp. 495-516.
Tinanoff N. Clinical decision making for caries management in children. Pediatr Dent. 2002; 24 (5): 386-392.
Carranza A. Periodontología clínica. 9a edición. México: McGraw Gill; 2002. p. 571.
Malamed S. Clinical action of specific agents. Handbook of local anesthesia. 4a ed. España: Ed. Harcourt; 1997. p. 4674.
— Salazar N, Berron R, Ortega M, Onuma E. Asma y neutropenia cíclica. Alergol et Inmunopathol. 1996; 24 (1): 25-28.
— Hammond WP, Price TH, Dale DC. Treatment of cyclic neutropenia with granulocyte colony stimulating factor. N Engl J Med. 1989; 320: 1306-1311.
— Boxer L, Dale DC. Neutropenia: causes and consequences. Semin Hematol. 2003; 39: 75-81.
— Dale DC, Bolyard AA, Aprikyan A. Cyclic neutropenia. Semin Hematol. 2002; 39: 89-94.
— Migliaccio AR, Dale DC. Hematopoyetic progenitors in cyclic neutropenia: effect of granulocyte colony-stimulating factor in vivo. Blood. 1990; 75: 1951-1959.
— Li FQ, Howitz M. Characterization of mutant neutrophil elastase in severe congenital neutropenia. J Biol Chem. 2001; 276: 14230-14241.
— Hunter MG, Avalos BR. Granulocyte colony-stimulating factor receptor mutations in severe congenital neutropenia transforming to acute mielogenous leukemia confer resistance to apoptosis and enhance cell survival. Blood. 2000; 95: 2132-2137.
— Ross D, Law SK. Hematologically important mutations: leukocyte adhesion deficiency. Blood Cell Mol Dis. 2001; 27: 1000-1004.
— Ward AC, van Aesch YM, Schelen AM. Defective internalization and sustained activation of truncated granulocyte colony-stimulating factor receptor found in severe congenital neutropenia/acute myeloid leukemia. Blood. 1999; 93: 447-458.
— Dong F, Dale DC, Bonilla MA. Mutations in the granulocyte colony-stimulating factor receptor gen in patients whit severe congenital neutropenia. Leukemia. 1997; 11: 120-125.
— Welte K, Boxer LA. Severe chronic neutropenia: pathophysiology and therapy. Semin Hematol. 2997; 34: 277-278.
— Lange RD, Jones JB. Cyclic neutropenia. Review of clinical manifestation and management. Am J Pediatr Hematol Oncol. 1981; 3: 363-367.